Detalles de la búsqueda
1.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Antimicrob Agents Chemother
; 68(1): e0078123, 2024 Jan 10.
Artículo
Inglés
| MEDLINE | ID: mdl-38038460
2.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artículo
Inglés
| MEDLINE | ID: mdl-32130806
3.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artículo
Inglés
| MEDLINE | ID: mdl-32130809
4.
Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV.
Qual Life Res
; 32(2): 531-541, 2023 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-36512302
5.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artículo
Inglés
| MEDLINE | ID: mdl-33308425
6.
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
BMC Infect Dis
; 22(1): 428, 2022 May 04.
Artículo
Inglés
| MEDLINE | ID: mdl-35508986
7.
Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries.
Sex Transm Infect
; 97(8): 566-573, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-33632889
8.
Dose-related and contextual aspects of suboptimal adherence to antiretroviral therapy among persons living with HIV in Western Europe.
Eur J Public Health
; 31(3): 567-575, 2021 07 13.
Artículo
Inglés
| MEDLINE | ID: mdl-33462616
9.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav
; 24(12): 3533-3544, 2020 Dec.
Artículo
Inglés
| MEDLINE | ID: mdl-32447500
10.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lancet HIV
; 11(4): e222-e232, 2024 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-38538161
11.
Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV.
Adv Ther
; 40(12): 5300-5314, 2023 12.
Artículo
Inglés
| MEDLINE | ID: mdl-37776478
12.
Adherence to oral antiretroviral therapy in Canada, 2010-2020.
AIDS
; 37(13): 2031-2040, 2023 11 01.
Artículo
Inglés
| MEDLINE | ID: mdl-37418513
13.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artículo
Inglés
| MEDLINE | ID: mdl-37567205
14.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS
; 36(2): 185-194, 2022 02 01.
Artículo
Inglés
| MEDLINE | ID: mdl-34261093
15.
Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
PLoS One
; 16(2): e0245955, 2021.
Artículo
Inglés
| MEDLINE | ID: mdl-33529201
16.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Patient
; 14(6): 849-862, 2021 11.
Artículo
Inglés
| MEDLINE | ID: mdl-34056699
17.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artículo
Inglés
| MEDLINE | ID: mdl-33794181
18.
Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV.
Patient
; 13(4): 409-422, 2020 08.
Artículo
Inglés
| MEDLINE | ID: mdl-32356146
19.
Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Value Health Reg Issues
; 16: 74-80, 2018 Sep.
Artículo
Inglés
| MEDLINE | ID: mdl-30296624
Resultados
1 -
19
de 19
1
Próxima >
>>